CMO Chart Subscribe

Johanna Mercier

Chief Commercial & Corporate Affairs Officer, Gilead Sciences

Healthcare & Pharma · B2B · Enterprise

Named in: S&P 500 company

205
tied (T-205), outside the Top 100 Preliminary — November 2026 score 45.5

100 in Enterprise · T-105 in B2B · 5 of 43 in Healthcare & Pharma

600 500 400 300 200 100
90% range of the rank: the data cannot tell these places apart Nov range 124 to 523

Top signals: Byline in oncodaily.com (Sep 21); Quoted in trinidadexpress.com (Sep 20)

Score breakdown

Measures on a 0 to 100 scale against this month's base of 2,056 CMOs.

45.5 out of 100: the weighted sum of the measures below.

  1. Visibility 30% of this score · last 90 days 22.5

    How much the press wrote about them. An interview or a column counts in full, a quote in a story about the company counts a little, a passing mention or a press release counts zero. Big-company coverage is scaled down so the employer's brand does not carry the person.

  2. Engagement 20% of this score · last 90 days 99.8

    How people respond to their LinkedIn posts: the median post, both in absolute terms and per 1,000 followers, so a huge account does not win by size alone.

  3. Authority 20% of this score · last 12 months, fading 37.2

    The longer track record: press over the past year with older pieces fading, plus awards and major lists.

  4. AI recall 15% of this score · quarterly 63.8

    Whether AI assistants know who they are without searching the web, asked several times per model and graded by a separate check. Wrong answers do not count.

  5. Consistency 15% of this score · last 90 days 12.1

    Showing up steadily: active weeks on LinkedIn and months with press, on a square-root curve, so posting three times a day does not help.

LinkedIn, last 90 days

Followers
5,782
Own posts
1
Active weeks of 13
1
Median engagement per post
1,247

Engagement is reactions + 2 × comments + 3 × reposts on the person's own posts; reposts of company content are not counted. LinkedIn profile.

Press, awards and talks

Earned coverage from the last 12 months that we confirmed is about Johanna Mercier, not a namesake. Each item links to the source. Press releases and company newsrooms are not counted.

  1. ColumnT3 Johanna Mercier: A New Pathway for HIV Prevention Across the Americas (opens in a new tab) · oncodaily.com
  2. QuotedT2 More access to HIV drugs (opens in a new tab) · trinidadexpress.com
  3. QuotedT3 Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances (opens in a new tab) · Yahoo Finance

Rank history starts with this chart. From the next chart on, this page shows each month's rank and range.